Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

NCT02728752 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatomyositis

Interventions

DRUG: Octagam 10%
OTHER: Placebo

Sponsor

Octapharma